Abstract
AbstractThe diagnosis of Waldenström’s macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease presentation. Furthermore, in recent years, WM has witnessed remarkable progress on the diagnostic front, as well as a deeper understanding of the disease biology, which has affected clinical practice. This, together with the increasing variety of tools and techniques available, makes it necessary to have a practical guidance for clinicians to perform the initial evaluation of patients with WM. In this paper, we present the consensus recommendations and laboratory requirements for the diagnosis of WM developed by the European Consortium of Waldenström’s Macroglobulinemia (ECWM), for both clinical practice as well as the research/academical setting. We provide the procedures for multiparametric flow cytometry, fluorescence in situ hybridization and molecular tests, and with this offer guidance for a standardized diagnostic work-up and methodological workflow of patients with IgM monoclonal gammopathy of uncertain significance, asymptomatic and symptomatic WM.
Funder
Roche
Janssen Pharmaceuticals
Gilead Foundation
Amgen
Bristol-Myers Squibb Company | Bristol-Myers Squibb Canada
Celgene
Novartis Pharmaceuticals Corporation
Sanofi
Takeda Pharmaceuticals U.S.A.
AstraZeneca
European Hematology Association
Associazione Italiana per la Ricerca sul Cancro
AbbVie
Bayer
Celltrion Healthcare
Pfizer
Meso Scale Diagnostics
Janssen Biotech
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献